Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 19/20 | 0.84 |
| ▸ | MMP9 | P14780 | 16/20 | 0.84 |
| ▸ | MMP1 | P03956 | 15/20 | 0.84 |
| ▸ | ADAM17 | P78536 | 10/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7319243 | 0.92 | MMP13 (0.93) | MMP13MMP9MMP1ADAM17TDP1 | |
| SCHEMBL7453410 | 0.92 | MMP13 (1.00) | MMP13MMP9MMP1ADAM17TDP1 | |
| SCHEMBL6129978 | 0.92 | MMP13 (1.00) | MMP13MMP9MMP1ADAM17TDP1 | |
| SCHEMBL7316679 | 0.90 | MMP13 (1.00) | MMP13MMP9MMP1ADAM17TDP1 | |
| SCHEMBL7317442 | 0.90 | MMP13 (1.00) | MMP13MMP9MMP1ADAM17TDP1 | |
| SCHEMBL6129932 | 0.89 | MMP13 (0.81) | MMP13MMP9MMP1ADAM17TDP1 | |
| SCHEMBL6129964 | 0.88 | MMP13 (1.00) | MMP13MMP9MMP1ADAM17 | |
| SCHEMBL3949565 | 0.85 | MMP13 (0.78) | MMP13MMP9MMP1ADAM17TDP1 | |
| SCHEMBL7313411 | 0.85 | MMP13 (0.80) | MMP13MMP9MMP1ADAM17TDP1 | |
| SCHEMBL5094542 | 0.84 | MMP13 (1.00) | MMP13MMP9MMP1ADAM17TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030035332-A1 | The preparation and use of ortho-sulfonamido arylhydroxamic acids as matrix metalloproteinase inhibitors | WYETH | 2003-02-20 | — | — | US | claimed |
| EP-1259488-A1 | ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth (US) | 2002-11-27 | — | — | EP | claimed |
| US-20020169184-A1 | PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-11-14 | — | — | US | claimed |
| US-6465508-B1 | NONPEPTIDE INHIBITORS OF GELATINASES, STROMELYSINS AND COLLA-GENASES; ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, HIV | WYETH | 2002-10-15 | — | — | US | claimed |
| WO-2001062733-A1 | ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2001-08-30 | — | — | WO | claimed |
| US-6934639-B1 | Methods for designing agents that interact with MMP-13 | WYETH (US) | 2005-08-23 | — | — | US | disclosed |
| EP-1274980-A4 | SOLUTION AND CRYSTAL STRUCTURES OF MMP-13 ACTIVE SITE AND USES THEREOF | WYETH CORP (US) | 2005-02-09 | — | — | EP | disclosed |
| US-6825352-B2 | ANTIARTHRITIC, ANTITUMOR, ANTIMETASTASIS, ANTIULCER, AND WOUND HEALING AGENTS; BONE, NERVOUS SYSTEM, DEGENERATIVE JOINT DISORDERS; PROTEINURIA, ANEURYSMS, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTIONS | WYETH | 2004-11-30 | — | — | US | disclosed |
| US-20030035332-A1 | The preparation and use of ortho-sulfonamido arylhydroxamic acids as matrix metalloproteinase inhibitors | WYETH | 2003-02-20 | — | — | US | disclosed |
| EP-1274980-A1 | SOLUTION AND CRYSTAL STRUCTURES OF MMP-13 ACTIVE SITE AND USES THEREOF | Wyeth (US) | 2003-01-15 | — | — | EP | disclosed |
| EP-1259488-A1 | ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020169184-A1 | PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-11-14 | — | — | US | disclosed |
| US-6465508-B1 | NONPEPTIDE INHIBITORS OF GELATINASES, STROMELYSINS AND COLLA-GENASES; ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, HIV | WYETH | 2002-10-15 | — | — | US | disclosed |
| WO-2001062733-A1 | ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001063244-A1 | SOLUTION AND CRYSTAL STRUCTURES OF MMP-13 ACTIVE SITE AND USES THEREOF | WYETH (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169184-A1 | PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP1, MMP7, MMP2 | MMP13 9/4885MMP9 21/4885MMP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.